◀ Back to PCNA
EGFR — PCNA
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Psyrri et al., Med Oncol 2006
(Carcinoma, Squamous Cell...) :
Cyclin dependent kinases, the tumor suppressor p53 gene, and
epidermal growth factor receptor are some of the molecular targets of such therapies in patients with SCCHN
Rougier et al., Semin Oncol 2007
(Carcinoma, Hepatocellular...) :
Possible future therapeutic strategies include
epidermal growth factor receptor inhibitors, antivascular endothelial growth factor therapies,
cyclin D
inhibitors , and HMG-CoA reductase inhibitors
Yang et al., Biochem J 2008
(Breast Neoplasms) :
Inhibition of
EGFR , PI3K ( phosphoinositide 3-kinase ; kinases required for Rac activation by HRG ) or MEK [ MAPK ( mitogen activated protein kinase ) /ERK ( extracellular-signal regulated kinase ) kinase ] also
blocked the up-regulation of
cyclin D1 and p21(Cip1) by HRG
Lee et al., American journal of physiology. Renal physiology 2008
:
Consequently, the inhibition of Ca ( 2+ ), PKC,
EGFR , p44/42 MAPKs, or NF-kappaB
blocked the BSA induced increases in cyclin D1,
cyclin dependent kinase (CDK)4 , cyclin E, or CDK2 and restored the BSA induced inhibition of p21 ( WAF/Cip1 ) and p27 ( Kip1 ) expression